SI
SI
discoversearch

Biotech / Medical
Provectus Pharmaceuticals Inc.
An SI Board Since April 2006
Posts SubjectMarks Bans Symbol
13038 110 0 PVCT
Emcee:  Jack Russell Type:  Moderated



This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic.

Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. The product pipeline includes:

PV-10 For Metastatic Melanoma A Phase 2 clinical trial has been successfully completed, and preparations are underway for a Phase 3 randomized controlled study suitable for Special Protocol Assessment. Paths for accelerated approval for PV-10 to treat metastatic melanoma in the USA and abroad are being evaluated. PV-10 has received Orphan Drug Designation from the US FDA for the treatment of melanoma. PV-10 For Metastatic Liver Cancer A Phase 1 clinical trial is currently underway.PV-10 has received Orphan Drug Designation from the US FDA for the treatment of liver cancer. PV-10 For Recurrent Breast Cancer A Phase 1 clinical trial has been successfully completed.A Compassionate Use Program for PV-10 is being conducted as an expanded access study.

Provectus' product pipeline also includes advanced therapies being developed to treat severe psoriasis and atopic dermatitis.

PH-10 For Psoriasis A Phase 2 clinical trial has been successfully completed.A Phase 2c randomized clinical trial is currently underway. PH-10 For Atopic Dermatitis A Phase 2 clinical trial has been successfully completed.

Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.

Additionally, Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.

For further information, read detailed Research Reports

------------------------------------------------------------------------------------------------------------------------------------------------------

Provectus Pharmaceuticals Launches Free Mobile Investor Relations ApplicationThursday January 24, 2013KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has launched a free mobile shareholder investor relations application.

The "Provectus IR" App is available for download from the App Store at www.itunes.com/appstore and from the Google Play Store at play.google.com. The investor relations application offers immediate portable access to the Company's latest news, financial information, presentations, and factsheet.

-------------------------------------------------------------------------------------------------------------------------------------------------------



Provectus Web Presentation: HIGHLY RECOMMENDED VIEWING
"Opening a new front in the war against Cancer"
pvct.com



VIDEO AND AUDIO:



*PV-10 link to video and visual references:

http://www.pvct.com/multimedianews.html





PV-10 Trial Participants Telling Their Own Stories in the News

http://www.pvct.com/pv10-videos.html





May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.
Video can be viewed here.

http://www.pvct.com/hersey_pv10_video.html?pg=2

This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.
Video can be viewed here.
http://www.pvct.com/hersey_pv10_video.html?pg=5





2008, Charles Dawson, PV10 patient, Australia; Professor John Thompson, Sydney Melanoma Unit

Video can be viewed here

https://www.youtube.com/watch?v=HSjoev_q9Nw





December 16, 2010
Madja Rauh recently traveled to Bethlehem with her daughter Ursa Rauh from Ljubljana, the capital of Slovenia in Europe, to receive a promising, experimental treatment for metastatic melanoma with internationally recognized melanoma investigator Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology, St. Luke's Hospital & Health Network,Bethlehem, PA

Video can be viewed here.

http://www.slhn.org/News/2010/Slovenian-Woman-Receives-Treatment

http://www.pvct.com/inthenews.html?article=20110725&mode=0
Madja Rauh, PV10 patient, has a Facebook page as of 1/ 2015





http://www.pvct.com/inthenews.html?article=20070321&mode=0






http://www.pvct.com/inthenews.html?article=20110725&mode=0
Madja Rauh, PV-10 patient, has a Facebook page as of January 2015





May/June 2014

“Very Impressive Data” for Rose Bengal 10% in Intralesional Melanoma

Merrick Ross, chief of the melanoma section in the Department of Surgical Oncology at MD Anderson Cancer Center in Houston, says a phase 2 trial of Rose Bengal 10% as a chemical ablative agent injected directly into melanoma tumors yielded “very impressive data.” Even “bystander” lesions that were not injected showed good partial and complete responses, confirming the agent’s systemic value. Because of low toxicity, the treatment could be useful not only in combination with other therapies but as monotherapy for patients who aren’t good candidates for more toxic systemic treatments. American Society of Clinical Oncology, May/June 2014

Video can be viewed here.

http://www.ptcommunity.com/video/very-impressive-data-rose-bengal-10-intralesional-melanoma


--------------------------------------------------------------





PV-10 Audio References:

May 9, 2014 Dr. Sanjiv Agarwala Discusses PV-10 on Daybreak USA

On a recent airing of USA Radio National's Daybreak USA, host Jay Young interviewed Dr. Sanjiv S. Agarwala of St. Luke's Cancer Center in recognition of melanoma awareness month. Dr. Agarwala discusses melanoma risks and treatment as well as exciting results from his clinical work with treating advanced melanoma with PV-10.

With the permission of USA Radio National, an audio track containing the interview that aired on Daybreak USA is available at:

https://www.pvct.com/inthenews.html?article=20140509&mode=0



--------------------------------------------------------------

PVCT insiders transactions:
secform4.com

--------------------------------------------------------------


Contact Info

Our Contact Form
Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005
info@pvct.com

Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA • MAP

Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
Laura Skorny
1717 Arch Street, Suite 1300
Philadelphia, PA 19103
E-mail: Laura.Skorny@Broadridge.com
Telephone: +1 (610) 649-7300
Fax: +1 (610) 649-7302


Investor Relations:
Porter, LeVay & Rose, Inc.
Marlon A. Nurse
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
Fax: 212-244-3075
marlon@plrinvest.com


Media Relations:
Porter, LeVay & Rose, Inc.
Bill Gordon
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
bill@plrinvest.com


Investment Advisor:
Network 1 Financial Securities
Damon Testaverde
Telephone: +1 (800) 205-8031



--------------------------------------------------------------
Company Website


pvct.com

==============================================================
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
13038FDA Meeting PR! finance.yahoo.com Provectus Biopharmaceuticals Met with FDA onJack Russell-February 9
13037Thanks Howard great interview...Jack Russell-January 20
13036The WallStreet Transcript Interviews Peter Culpepper, CFO, COO Tuesday JanuarHoward Williams-January 20
13035Small Cap IR Analyst coverage this morning... finance.yahoo.comJack Russell-January 12
13034LOL...what does the diluted SP look like? Hope 2015 turns out much better for tNTTG-January 5
13033New CTD Blog... provectuspharmaceuticalsinc.blogspot.comJack Russell-January 5
13032Oops! Unfortunately, Mimbari was apparently wrong. Yesterday I was involved inHoward Williams-January 4
13031Worth rereading ....... Message 29054664Howard Williams-January 3
13030Provectus Biopharmaceuticals' Protocol for Phase 2 Study of Mechanism of ActHoward Williams-12/23/2014
13029Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 PhHoward Williams-12/22/2014
13028New Alan Ross article about PV-10 and liver cancer Published this morning .....Howard Williams-12/20/2014
13027Peter Culpepper video interview.... youtube.comJack Russell-12/18/2014
13026It does appear that Pfizer is stacking the deck on PVCT's SAB Jack, suggestiHoward Williams-12/17/2014
13025Pfizer with a third member to the SAB.... Worldwide expert on new drug pricing..Jack Russell-12/17/2014
13024PROVECTUS BIOPHARMACEUTICALS TO SPONSOR AMERICAN ASSOCIATION OF PHYSICIANS OF INHoward Williams-12/17/2014
13023Good Read from the Journal of Surgical Oncology By Merrick Ross... eorder.sheridJack Russell112/11/2014
13022Interesting piece on insider trading... Involves Dendreons Cancer drug and the FJack Russell-12/10/2014
13021Great well thought out response by Alan....Jack Russell-12/9/2014
13020Alan Ross took the time to make an excellent response to yesterday's very poHoward Williams112/9/2014
13019Cancer Connect article... news.cancerconnect.comJack Russell-12/8/2014
13018Provectus News Oncologists examine efficacy of rose bengal against cancer FrHoward Williams-12/5/2014
13017BBC Cancer in China... bbc.comJack Russell-11/17/2014
13016Hi Jack, Could you please upload a logo into the logo field on your board? IfSI Ron (Hall Monitor)-11/13/2014
13015This is an unfortunate protocol for PV-10NTTG-11/13/2014
13014NEWS -- Provectus Biopharmaceuticals’ Protocol for Phase 3 Study Of PV-10 As TreJack Russell-11/13/2014
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2015 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.